 Patients with histologically or cytologically advanced solid tumours who have progressed on at least one prior chemotherapy regimen for advanced cancer with a PIK3CA mutation detected from tumour andor circulating tumour DNA. Patients with HER2 positive breast cancer should have progressed on at least two prior HER2 directed therapies for advanced breast cancer. 